Simon N. Pimstone - Mar 7, 2023 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Cassandra Robinson, Power of Attorney
Stock symbol
XENE
Transactions as of
Mar 7, 2023
Transactions value $
-$661,251
Form type
4
Date filed
3/9/2023, 05:21 PM
Previous filing
Aug 16, 2022
Next filing
Jun 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $110K +41.2K +685.87% $2.68* 47.2K Mar 7, 2023 Direct F1
transaction XENE Common Shares Tax liability -$80.2K -2.16K -4.58% $37.13 45K Mar 7, 2023 Direct F2
transaction XENE Common Shares Sale -$407K -11K -24.43% $37.01 34K Mar 7, 2023 Direct F3
transaction XENE Common Shares Options Exercise $79.9K +30.9K +90.77% $2.59* 64.9K Mar 7, 2023 Direct F1
transaction XENE Common Shares Tax liability -$60.1K -1.62K -2.49% $37.13 63.2K Mar 7, 2023 Direct F2
transaction XENE Common Shares Sale -$304K -8.24K -13.03% $36.94 55K Mar 7, 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -41.2K -100% $0.00* 0 Mar 7, 2023 Common Shares 41.2K $2.68 Direct F1, F5, F6
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -30.9K -100% $0.00* 0 Mar 7, 2023 Common Shares 30.9K $2.59 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F2 Represents the closing price of the Company's common shares on March 6, 2023 for purposes of net settlement calculations.
F3 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.93 to $37.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.89 to $37.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 The shares subject to the options are fully vested and exercisable.
F6 Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period.